Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $30

Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $25 to $30.